Leerink Swann lowered shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an outperform rating to a market perform rating in a research note released on Thursday. Leerink Swann currently has $40.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $107.00.

Several other research firms have also issued reports on ALNY. Jefferies Group restated a buy rating and set a $80.00 price target (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 25th. FBR & Co reaffirmed an outperform rating and set a $180.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 27th. Morgan Stanley set a $93.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, September 6th. Finally, Barclays PLC downgraded shares of Alnylam Pharmaceuticals from an overweight rating to an equal weight rating and reduced their price objective for the stock from $85.00 to $50.00 in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of Buy and a consensus price target of $85.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.94% on Thursday, hitting $34.42. 2,758,205 shares of the stock were exchanged. Alnylam Pharmaceuticals has a one year low of $34.18 and a one year high of $110.75. The company has a 50 day moving average of $71.80 and a 200 day moving average of $66.24. The stock’s market capitalization is $2.95 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the business earned ($0.85) EPS. The company’s revenue was up .2% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.00% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Dodge & Cox bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $139,650,000. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares during the last quarter. Bridger Management LLC acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $50,041,000. Slate Path Capital LP boosted its stake in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares during the last quarter. Finally, Deerfield Management Co. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $18,645,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.